Monitor for topline data from the pilot study in the second half of 2026, which could serve as a key catalyst for the stock. The absence of near-term financial impact makes this a longer-term developmental milestone.
Price Chart
Executive Summary
Eton Pharmaceuticals announced the initiation of a pilot clinical study for its product candidate ET-700, an extended-release formulation of zinc acetate for the treatment of Wilson disease. The first patient has been dosed, with topline results expected in the second half of 2026.
Key Facts
- Eton Pharmaceuticals initiated a pilot clinical study for ET-700, an extended-release formulation of zinc acetate for Wilson disease.
- The study is a double-blinded, placebo-controlled trial with 36 healthy volunteers comparing ET-700, Galzin, and placebo.
- Topline results are expected in the second half of 2026, with a pivotal study planned for early 2027 if results are positive.
- CEO Sean Brynjelsen stated ET-700 could exceed $100 million in peak annual U.S. sales if approved.
Financial Impact
Potential for over $100 million in peak annual U.S. sales if ET-700 is approved, though no immediate financial impact is expected from study initiation.
Risk Factors
- Clinical trial may not demonstrate efficacy or safety advantages over existing treatment (Galzin).
- Regulatory approval is uncertain and may require additional trials beyond the planned pivotal study.
- Market competition and commercialization challenges could limit peak sales potential despite positive trial results.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-013369 |
| Exhibit: ex_940424.htm | 0001437749-26-013369 |
| Document: 0001437749-26-013369-index-headers.html | 0001437749-26-013369 |
| Document: 0001437749-26-013369-index.html | 0001437749-26-013369 |
| Document: 0001437749-26-013369.txt | 0001437749-26-013369 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $52.88 | awaiting T+60 | — | $50.42 (−4.65%) |
Oct 6, 2026 20d ago | 144 | $54.88 | awaiting T+60 | — | $50.42 (−8.13%) |
Sep 28, 2026 29d ago | 8-K | $59.18 | awaiting T+60 | — | $50.42 (−14.80%) |
Aug 31, 2026 8w ago | Insider Cluster | $60.43 | awaiting T+60 | — | $50.42 (−16.56%) |
Aug 28, 2026 8w ago | Insider Cluster | $60.44 | awaiting T+60 | — | $50.42 (−16.58%) |
Aug 24, 2026 9w ago | Insider Cluster | $63.05 | awaiting T+60 | — | $50.42 (+20.03%) |
Aug 19, 2026 9w ago | 144 | $61.48 | awaiting T+60 | — | $50.42 (+17.99%) |
Aug 5, 2026 11w ago | 8-K | $45.97 | awaiting T+60 | — | $50.42 (+9.68%) |
Aug 5, 2026 11w ago | Press Release | $45.97 | awaiting T+60 | — | $50.42 (+9.68%) |
Aug 4, 2026 12w ago | 8-K | $45.83 | awaiting T+60 | — | $50.42 (+10.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers